What is a stock summary page? Click here for an overview.
Business Description
Vanda Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US9216591084
Share Class Description:
LTS:0LKB: Ordinary SharesDescription
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 30.31 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.9 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.2 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.39 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.39 | |||||
| 9-Day RSI | 49.62 | |||||
| 14-Day RSI | 51.85 | |||||
| 3-1 Month Momentum % | -4.49 | |||||
| 6-1 Month Momentum % | -3.72 | |||||
| 12-1 Month Momentum % | -57.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | |||||
| Quick Ratio | 4.37 | |||||
| Cash Ratio | 3.75 | |||||
| Days Inventory | 49.49 | |||||
| Days Sales Outstanding | 74.4 | |||||
| Days Payable | 148.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 0.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.31 | |||||
| Operating Margin % | -20.46 | |||||
| Net Margin % | -9.51 | |||||
| FCF Margin % | -8.17 | |||||
| ROE % | -3.49 | |||||
| ROA % | -2.9 | |||||
| ROIC % | -12.12 | |||||
| 3-Year ROIIC % | -52.53 | |||||
| ROC (Joel Greenblatt) % | -425.88 | |||||
| ROCE % | -7.29 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 23.15 | |||||
| Shiller PE Ratio | 24.68 | |||||
| PS Ratio | 1.43 | |||||
| PB Ratio | 0.53 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| EV-to-EBIT | 2.05 | |||||
| EV-to-EBITDA | 2.57 | |||||
| EV-to-Revenue | -0.42 | |||||
| EV-to-FCF | 4.64 | |||||
| Price-to-GF-Value | 0.92 | |||||
| Price-to-Projected-FCF | 0.38 | |||||
| Price-to-Median-PS-Value | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 0.87 | |||||
| Price-to-Net-Cash | 1.08 | |||||
| Earnings Yield (Greenblatt) % | 48.77 | |||||
| FCF Yield % | -5.83 | |||||
| Forward Rate of Return (Yacktman) % | -2.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vanda Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 198.772 | ||
| EPS (TTM) ($) | -0.32 | ||
| Beta | 0.38 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 31.05 | ||
| 14-Day RSI | 51.85 | ||
| 14-Day ATR ($) | 0.163292 | ||
| 20-Day SMA ($) | 4.818706 | ||
| 12-1 Month Momentum % | -57.65 | ||
| 52-Week Range ($) | 4.235 - 10.39 | ||
| Shares Outstanding (Mil) | 58.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vanda Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vanda Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vanda Pharmaceuticals Inc Frequently Asked Questions
What is Vanda Pharmaceuticals Inc(LTS:0LKB)'s stock price today?
The current price of LTS:0LKB is $4.83. The 52 week high of LTS:0LKB is $10.39 and 52 week low is $4.24.
When is next earnings date of Vanda Pharmaceuticals Inc(LTS:0LKB)?
The next earnings date of Vanda Pharmaceuticals Inc(LTS:0LKB) is 2025-05-08 Est..
Does Vanda Pharmaceuticals Inc(LTS:0LKB) pay dividends? If so, how much?
Vanda Pharmaceuticals Inc(LTS:0LKB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers